Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-1: WZTL-002 in B-cell Lymphoma
NCT04049513Phase 1Active, not recruiting
- Sponsor
- Malaghan Institute of Medical Research
- Start
- Oct 2019
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 1928zT2 CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by Malaghan Institute of Medical Research. Primary endpoint: Number and severity of adverse events at 3 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
1928zT2 CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04049513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049513.